Q3 2023 Results

Company overview Financial review Conclusions Appendix References Novartis delivers strong sales growth, robust margin expansion and raises guidance. Successfully spun Sandoz SUMMARY Growth and productivity1 % CC Core margin 37.4% (+270 bps) Core margin 36.9% (+290 bps) Successful spin-off of Sandoz Completed October 4, 2023 Several major innovation milestones in Q3 CosentyxⓇ IV formulation approved in US (PSA, AS, nr-axSpA) LeqvioⓇ approved in China and Japan KisqaliⓇ submitted in EU; US submission planned in Q4 2023 Clinically meaningful and statistically significant ■ 21% 19% ■ 12% 10% Sales Core Opinc Sales Q3 Core Oplnc 9M FY 2023 guidance raised¹ Sales expected to grow high single digit; Core Oplnc expected to grow mid to high teens (from low double digit to mid teens) Ph3 data for multiple assets with blockbuster potential ■ PluvictoⓇ mCRPC pre-taxane ■ Iptacopan IgAN ■ Remibrutinib CSU ■ LutatheraⓇ GEP-NETS 1. Continuing operations. Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 48 of Condensed Interim Financial Report. Unless otherwise noted, all growth rates refer to same period in PY. Oplnc operating income. 4 Investor Relations | Q3 2023 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation